CAT scan of brain, Alzheimer's disease (Credit: Getty Images)
May 3, 2023 06:00 AM EDTUpdated 07:45 AM
R&D

Lil­ly’s Alzheimer’s drug do­nanemab slows cog­ni­tive de­cline by 35% in PhI­II, set­ting up show­down with Ei­sai’s Leqem­bi

Ryan Cross

Senior Science Correspondent

At long last, Eli Lil­ly has found suc­cess in its decades-long ef­fort to de­vel­op a treat­ment for Alzheimer’s dis­ease.

The com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times